Relevant Issues in the Monitoring and the Toxicology of Antidepressants
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This review provides specific information concerning the interpretation and usefulness of antidepressant drug monitoring. Fifteen antidepressants (ADs) were selected based on their importance in the 7 major markets (Japan, USA, France, United Kingdom, Italy, Spain, Germany) according to the Cognos Plus Study #11. Literature data were reviewed concerning monitoring of the tricyclic ADs amitriptyline, clomipramine, imipramine, and new generation antidepressants such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, mianserin, mirtazapine, bupropion, and milnacipran. In addition, St.-John's Wort was added as this natural antidepressant is very popular in Europe. The objectives of therapeutic drug monitoring (TDM) for old and new generation ADs differs, as older ADs have narrow therapeutic windows with higher risks of severe drug interactions, while the new ADs have a wide therapeutic range, but an unclear plasma concentration-effect relationship. Therefore, the purpose of TDM for new-generation ADs leads more to the monitoring of patient compliance and special patient groups such as the elderly, patients with liver and kidney impairment, patients with poor metabolism by CYP 450 and comedication with inhibitors and inducers of those enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Dwivedi, Y., Rizavi, H. S., Conley, R. R., Roberts, R. C., Tamminga, C. A., & Pandey, G. N. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.8.804 · Cited by 875
Personality as independent predictor of long-term mortality in patients with coronary heart disease
Denollet, J., Rombouts, H., Gillebert, T. C., Brutsaert, D. L., Sys, S. U., Brutsaert, D. L., & Stroobant, N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90007-0 · Cited by 679
Mechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540
Cohen, H. W., Gibson, G., & Alderman, M. H. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00301-0 · Cited by 390
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways
Taylor, C., Fricker, A. D., Devi, L. A., & Gomes, I. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2004.12.007 · Cited by 186
Suicide, depression, and antidepressants
Cipriani, A., Barbui, C., & Geddes, J. R. (2005) · BMJ · doi:10.1136/bmj.330.7488.373 · Cited by 102
Klier, C. M., Schmid-Siegel, B., Schäfer, M. R., Lenz, G., Saria, A., Lee, A., & Zernig, G. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0219 · Cited by 44
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Antidepressant-Induced Liver Injury: A Review for Clinicians
Voican, C. S., Corruble, E., Naveau, S., & Perlemuter, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13050709 · Cited by 275
Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants
Hwang, J., Zheng, L. T., Ock, J., Lee, M. G., Kim, S.-H., Lee, H.-W., Lee, W.-H., Park, H.-C., & Suk, K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.045 · Cited by 181
Zhang, S., Li, B., Lovatt, D., Xu, J., Song, D., Goldman, S. A., Nedergaard, M., Hertz, L., & Peng, L. (2010) · Neuron Glia Biology · doi:10.1017/s1740925x10000141 · Cited by 69
“This concentration is lower than the combined plasma concentration of fluoxetine and its active metabolite, norfluoxetine (1–2 mM) in patients treated with fluoxetine (Bolo et al., 2000; Henry et al., 2005; Wille et al., 2008).”
Background
Metadata
- Authors
- Wille, S. M. R., Cooreman, S. G., Neels, H. M., & Lambert, W. E. E.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 45
- Issue
- 1
- Pages
- 25-89
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W2126856618
- Cited by
- 100
- References
- 10
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.